Related Experiment Video

Updated: Jan 7, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

The MEK-RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers

Eric Haines1, Michael Burke2, Rachel Catterall3

  • 1Ikena Oncology, Inc., Boston, MA, USA.

Nature Cancer
|January 2, 2026
PubMed

Insights

A novel MEK-RAF molecular glue, IK-595, offers improved antitumor activity and a wider therapeutic window for cancers driven by MAPK pathway alterations. This drug overcomes resistance and toxicity issues associated with current therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Mitogen-activated protein kinase (MAPK) pathway alterations are frequent drivers of cancer.
  • Approved therapies like RAS, MEK, and RAF inhibitors show limited clinical success due to resistance and toxicity.

Purpose of the Study:

  • To develop a novel therapeutic agent that overcomes the limitations of existing MAPK pathway inhibitors.
  • To introduce IK-595, a MEK-RAF molecular glue designed for enhanced efficacy and tolerability.

Main Methods:

  • Development of IK-595, a molecular glue targeting MEK and RAF proteins.
  • In vitro and in vivo studies to assess IK-595's mechanism of action, efficacy, and pharmacokinetic profile.
  • Evaluation of IK-595's ability to inhibit MAPK pathway reactivation and target engagement.

Main Results:

  • IK-595 effectively traps MEK in an inactive complex with all RAF isoforms.
  • The drug prevents MEK reactivation mediated by CRAF and ARAF heterodimerization, ensuring sustained MAPK pathway inhibition.
  • IK-595 demonstrated superior antitumor activity in various cancer models with MAPK pathway alterations.
  • Transient high plasma exposure of IK-595 resulted in an improved therapeutic window.

Conclusions:

  • IK-595 represents a potent MEK-RAF molecular glue with a unique mechanism of action.
  • Its prolonged target engagement, enhanced antitumor activity, and broader therapeutic window position it as a promising therapeutic option.
  • IK-595 is suitable for both monotherapy and combination treatments for MAPK pathway-driven cancers.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.6K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.3K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K